‹ Screener

Renalytix plc

RNLXY, RENXF · Services-Medical Laboratories · 331.2M shares · +11%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: $6M (gross $9M, SBC $3M)

Grade

D36

Medical-device company (the KidneyIntelX kidney-disease diagnostic) with operating losses and cash burn.

Strengths

Risks

Notable findings

Quarterly revenue

2023-12-31 · $709K2024-03-31 · $535K2024-06-30 · $586K2024-09-30 · $522K

Last 4 quarters · from SEC filings.

Key metrics

Gross margin
6.8%
Operating margin
-1293.5%
Net margin
-1461.6%
Return on equity
426.0%
Return on assets
-419.7%
Revenue growth (QoQ)
-10.9%
Current ratio
0.5×
EBITDA
-$29M
Tangible book value
-$9M
Cash & investments
$5M
Stock comp / revenue
74.7%

Notable events (8-K)

DateItems
2025-01-16Reg FDfiling ↗
2024-12-20Shareholder voteReg FDExhibitsfiling ↗
2024-11-19Material agreementDebt obligationExhibitsfiling ↗
2024-11-06Exec/director changeShareholder voteReg FDExhibitsfiling ↗
2024-10-01Material agreementAcquisition/dispositionResultsDebt obligationDelisting notice3.02OtherExhibitsfiling ↗
2024-08-27Delisting noticeReg FDExhibitsfiling ↗
2024-07-153.02Reg FDExhibitsfiling ↗
2024-06-25Auditor changeExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2025-01-162025-01-160001213900-25-004220 ↗
8-K2024-12-202024-12-190001213900-24-111219 ↗
8-K/A2024-11-192024-09-260001213900-24-100211 ↗
10-Q2024-11-192024-09-300000950170-24-128687 ↗
8-K2024-11-062024-10-310001213900-24-095002 ↗
8-K2024-10-012024-09-260001193125-24-230319 ↗
10-K2024-09-302024-06-300000950170-24-110315 ↗
8-K2024-08-272024-08-230000950170-24-100790 ↗
8-K2024-07-152024-07-150000950170-24-083385 ↗
8-K/A2024-06-252024-06-180000950170-24-077428 ↗
8-K2024-06-242024-06-180000950170-24-076873 ↗
8-K2024-06-242024-06-210000950170-24-076884 ↗